We combine a standardized human antigen challenge model in which we are able to measure the functional activity of specific immune response pathways, with two independent cohorts of active TB and two separate comparator populations of latent and cured infection, to provide compelling evidence that in vivo IL-17A/F responses are exaggerated in active disease. The gene discussed is IL17A; the disease is tuberculosis.